How Personalized Breast Cancer Care in 2025 Is Improving Survival and Quality of Life

Personalized Treatment Planning and Multidisciplinary Care

A breast cancer diagnosis leads to thorough assessment of the tumor’s characteristics, including:

• Pathology (cell type, grade, stage)
• Molecular markers (estrogen receptor [ER], progesterone receptor [PR], HER2 status, and others)
• Genomic profiling (using assays such as Oncotype DX or Mammaprint)
• Patient-related factors (age, comorbidities, goals, and preferences)

Treatment planning typically involves a multidisciplinary team—surgeons, oncologists, radiation therapists, and supportive care providers—to ensure patient-centered decisions based on the best available evidence. Seeking second opinions and engaging in shared decision-making are supported as part of the process.

Surgery: Lumpectomy, Mastectomy, and Reconstruction

Surgery often serves as a primary treatment, except in cases where pre-surgery (neoadjuvant) therapy is appropriate for tumor reduction. Surgical options include:

• Lumpectomy (breast-conserving surgery): Removal of the tumor with a margin of healthy tissue, aiming to preserve breast appearance.
• Mastectomy: Complete removal of one or both breasts, considered for higher-risk disease or based on patient preference.
• Reconstruction: May be performed immediately or at a later stage, using implants or tissue flaps, with the goal of supporting physical and psychological well-being.

Surgical approaches are individualized by tumor characteristics, patient health, genetic risk (such as BRCA mutations), and desired outcomes.

Axillary (lymph node) management: Most patients undergo sentinel lymph node biopsy, a minimally invasive staging procedure designed to help reduce the risk of lymphedema and other side effects. Axillary dissection is generally reserved for those with significant lymph node involvement.

Radiation Therapy: Shorter, High-Precision Regimens

Radiation therapy remains a key component of breast cancer care, especially following breast-conserving surgery, and is also utilized post-mastectomy in high-risk scenarios.

• Current practices: Many early-stage patients can receive shorter courses of radiation (3 weeks instead of 6), intended to decrease treatment burden and side effects.
• Intraoperative radiation therapy (IORT): In select cases, radiation may be delivered during surgery for added precision and convenience.

For high-risk cases (such as those with multiple involved lymph nodes or large tumors), regional nodal irradiation may be recommended based on the individual clinical context.

Systemic Therapies: Chemotherapy, Hormonal, Targeted, and Immunotherapy

Systemic treatment choices are informed by cancer biology rather than a universal approach.

Chemotherapy

• Used to target fast-growing cancer cells, administered before surgery (to reduce tumor size and potentially facilitate breast conservation) or after surgery (to help reduce recurrence risk).
• Standard for aggressive or advanced cancers, including triple-negative or HER2-positive subtypes.

Hormonal (Endocrine) Therapy

• Recommended for hormone receptor-positive (ER/PR+) cancers, generally continued for 5–10 years to lower recurrence risk.
• Common options include tamoxifen, aromatase inhibitors (letrozole, anastrozole), and ovarian suppression agents.

Targeted Therapy

• HER2-Positive: Agents such as trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu), given intravenously or by subcutaneous injection.
• Other targets: CDK4/6 inhibitors (abemaciclib [Verzenio], ribociclib [Kisqali]) are available for advanced and certain early-stage cancers, often as oral medications. Some additional targeted therapies address specific genetic mutations such as PI3K and ESR1, informed by mutational testing.

Immunotherapy

• Pembrolizumab (Keytruda): Approved for select early and advanced triple-negative breast cancers, usually combined with chemotherapy in defined settings. Eligibility for immunotherapy continues to expand as new clinical research emerges.

Genomic and Molecular Testing: Tailoring Therapy

Genomic tests such as Oncotype DX, Mammaprint, and PAM50 provide information on recurrence risk that can guide chemotherapy decisions for hormone receptor-positive, HER2-negative cancers. This testing helps determine when chemotherapy may be avoided, allowing for more individualized treatment plans.

Supportive, Complementary, and Palliative Care

Symptom management and quality of life are emphasized throughout the course of care:

• Early palliative (supportive) care is integrated at all stages to help manage side effects, pain, fatigue, nausea, sleep issues, and emotional concerns.
• Complementary therapies: Options like acupuncture and massage therapy may be incorporated into care plans for symptom relief, with consideration of patient expectations, cultural background, and availability.

Clinical Trials and Access to New Therapies

Participation in clinical trials offers opportunities to:

• Access new medications and treatment combinations,
• Benefit from innovative protocols (such as shorter radiation schedules or novel oral therapies),
• Learn about advances that may not yet be widely accessible.

Clinical trial enrollment is regulated for safety. Study-related medications are generally provided at no cost, and some trials offer travel or expense support.

Costs, Insurance, and Access

Most standard treatments and supportive therapies are covered by insurance in the US; however, access to certain advanced drugs, reconstructive surgery, or integrative therapies like acupuncture may vary. Patients are encouraged to consult with oncology financial counselors for guidance on insurance coverage, out-of-pocket expenses, and any available patient assistance programs.

Patient-Centered Decision-Making: Empowerment

Breast cancer care emphasizes the importance of patient participation by encouraging:

• Seeking second opinions,
• Taking an active role in treatment selection,
• Discussing costs, logistics, and personal priorities with the healthcare team.

This individualized approach, together with ongoing scientific advances, is associated with improvements in survival rates and patient quality of life in the United States.

Sources

• Cancer.gov – Breast Cancer Treatment (PDQ) for Health Professionals
• BreastCancer.org – Treatment Options
• Oncology Nursing News – Recent and Upcoming Advances in Breast Cancer Treatment

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.